Godet, Inês
Oza, Harsh H. http://orcid.org/0000-0001-6724-5975
Shi, Yi http://orcid.org/0009-0003-6807-0048
Joe, Natalie S.
Weinstein, Alyssa G. http://orcid.org/0000-0001-9342-0263
Johnson, Jeanette http://orcid.org/0000-0002-8268-5335
Considine, Michael
Talluri, Swathi
Zhang, Jingyuan
Xu, Reid
Doctorman, Steven
Mbulaiteye, Delma
Stein-O’Brien, Genevieve http://orcid.org/0000-0001-8681-9110
Kagohara, Luciane T. http://orcid.org/0000-0003-1706-0950
Santa-Maria, Cesar A.
Fertig, Elana J. http://orcid.org/0000-0003-3204-342X
Gilkes, Daniele M. http://orcid.org/0000-0003-3984-9338
Funding for this research was provided by:
U.S. Department of Health & Human Services | NIH | National Cancer Institute (P50CA006973)
The Jayne Koskinas Ted Giovanis Foundation for Health and Policy
Article History
Received: 10 March 2023
Accepted: 21 August 2024
First Online: 28 September 2024
Competing interests
: C.A.S. has received research funds from AstraZeneca, GSK/Tesaro, Merck, Gilead, Celldex, BMS, and Pfizer and has received consulting fees from Seattle Genetics. E.J.F. serves on the Scientific Advisory Board of Resistance Bio and is a consultant for Merck and Mestag Therapeutics and received research funding from Abbvie, Inc. and Roche/Genentech. The other authors have no competing interests to disclose.